Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study

NCT02423863 is registered in ClinicalTrials.gov with Oncovir, Inc. as lead sponsor.

NCT NCT02423863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02423863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study
Lead sponsor
Oncovir, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
August 31, 2020
Enrollment
26 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, melanoma, non-melanoma skin cancers, sarcoma